Boston-based Aktis Oncology (NASDAQ: AKTS) debuted on the Nasdaq on January 9, 2026, raising $318 million, marking one of the largest biotech IPOs in recent memory. The company, specializing in targeted alpha radiopharmaceuticals for cancer treatment, currently has a market cap of $3.34 billion. Aktis is known for developing precision cancer drugs that minimize harm to healthy tissue.
The global nuclear medicine market is projected to grow from nearly $18 billion in 2024 to almost $35 billion by 2030, with a compound annual growth rate of 10.16%. Notably, Eli Lilly (NYSE: LLY) has invested $100 million in Aktis, reinforcing their partnership to develop tumor-targeting therapies. This investment follows Eli Lilly’s earlier commitment of $60 million and a partnership established in 2024 aimed at advancing radiopharmaceuticals.
